Some of these aforementioned studies suggest that a deficiency in MMR protein expression or MSI-H tumor status may predict reduced benefit and potentially even detrimental impact of adjuvant therapy with a fluoropyrimidine alone in patients with stage II disease [120,126,127,128]. This evidence concerns the gene MRC1 and neoplasm.